Bendamustine's Emerging Role in the Management of Lymphoid Malignancies

Seminars in Hematology

Volumn 48, Issue SUPPL. 1, 2011, Pages

  Rummel, Mathias J ^a   Gregory, Stephanie A ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CAL 101; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GROWTH FACTOR; IBRITOMOMAB Y 90; LENALIDOMIDE; MITOXANTRONE; OFATUMUMAB; PREDNISONE; RITUXIMAB; RO 5072759; TEMSIROLIMUS; TOSITUMOMAB I 131; TRU 016; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; BLOOD TOXICITY; CANCER MORTALITY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; RECOMMENDED DRUG DOSE; SALVAGE THERAPY; SEPSIS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; NITROGEN MUSTARD COMPOUNDS;

EID: 79955392789     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.03.004     Document Type: Article

References (46)

1. Chow K.U., Sommerlad W.D., Boehrer S., et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002, 87:33-43.
2. Rummel M.J., Chow K.U., Hoelzer D., Mitrou P.S., Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol 2002, 29(Suppl 13):12-14.
3. Kath R., Blumenstengel K., Fricke H.J., Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001, 127:48-54.
4. Aivado M., Schulte K., Henze L., Burger J., Finke J., Haas R. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002, 29(Suppl 13):19-22.
5. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002, 128:603-609.
6. Bergmann M.A., Goebeler M.E., Herold M., et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005, 90:1357-1364.
7. Lissitchkov T., Arnaudov G., Peytchev D., Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006, 132:99-104.
8. Niederle N., Balleisen L., Heit W. Bendamustine vs fludarabine as second-line treatment for patients with chronic lymphocytic leukemia-first interim results of a randomized study. Ann Oncol 2008, 19(suppl 4). Abstract 379.
9. Knauf W.U., Lissichkov T., Aldaoud A., et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4378-4384.
10. Koppler H., Heymanns J., Pandorf A., Weide R. Bendamustine plus mitoxantrone-a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma 2004, 45:911-913.
11. Fischer K., Stilgenbauer S., Schweighofer C. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 2008, 112. Abstract 330.
12. Weide R., Pandorf A., Heymanns J., Koppler H. Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004, 45:2445-2449.
13. Fischer K., Cramer P., Stilgenbauer S., Busch R., Balleisen L., Kilp J. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 2009, 114. Abstract 205.
14. Knauf W., Lissitchkov T., Aldaoud A., et al. Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia. Blood 2010, 116. Abstract 2449.
15. Flinn I.W., Neuberg D.S., Grever M.R., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007, 25:793-798.
16. Johnson S., Smith A.G., Loffler H., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996, 347:1432-1438.
17. Leporrier M., Chevret S., Cazin B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98:2319-2325.
18. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750-1757.
19. Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009, 440-449.
20. Hallek M., Fingerle-Rowson G., Fink A.-M., et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008, 112. Abstract 325.
21. Bosch F., Ferrer A., Villamor N., et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008, 14:155-161.
22. Keating M.J., O'Brien S., Lerner S., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998, 92:1165-1171.
23. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975-980.
24. Cheson B.D. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995, 13:2431-2448.
25. Roue G., Lopez-Guerra M., Milpied P., et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008, 14:6907-6915.
26. Foon K.A., Boyiadzis M., Land S.R., et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:498-503.
27. Heider A., Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001, 12:725-729.
28. Friedberg J.W., Cohen P., Chen L., et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008, 26:204-210.
29. Kahl B.S., Bartlett N.L., Leonard J.P., et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010, 116:106-114.
30. Koenigsmann M., Knauf W., Herold M., et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma-a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004, 45:1821-1827.
31. Rummel M.J., Al-Batran S.E., Kim S.Z., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-3389.
32. Robinson K.S., Williams M.E., van der Jagt R.H., et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4473-4479.
33. Weide R., Hess G., Koppler H., et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007, 48:1299-1306.
34. Rummel M., Kaiser U., Balser C., Stauch M., Brugger W., Welslau M. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas-final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2010, 116. Abstract 856.
35. Rummel M., Niederle N., Maschmeyer G. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular indolent and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009, 114. Abstract 405.
36. Herold M., Schulze A., Niederwieser D., et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006, 132:105-112.
37. Horning S.J., Younes A., Jain V., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005, 23:712-719.
38. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:3262-3269.
39. Rummel M., von Grunhagen U., Niederle N., et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas-first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2007, 110. Abstract 385.
40. Salles G.A., Seymour J.F., Feugier P., Offner F., Lopez-Guillermo A., Bouabdallah R. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol 2010, 28(15s). Abstract 8004.
41. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
42. Goy A., Bernstein S.H., Kahl B.S., et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20:520-525.
43. Ansell S.M., Inwards D.J., Rowland K.M., et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008, 113:508-514.
44. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
45. Rummel M., Heine K., Bodenstein H., et al. Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients. J Clin Oncol 2008, 26(suppl). Abstract 8572.
46. Vacirca J.L., Acs P.I., Shimkus B.J., Rosen P.J. Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2010, 28(15s). Abstract 8041.